In this group of 233 patients with RET fusion–positive NSCLC, common treatment related adverse events (TRAE) of grade 3 or higher were neutropenia, (18%), hypertension (11%), and anemia (10%); there were no treatment-related deaths in this population [22]. Here, RET is linked to neutropenia.